"life science" - Knowledge Bank Results
US venture-backed buy-out activity held steady in the third quarter despite the deteriorating conditions in financial markets and mounting macroeconomic uncertainty, according to the latest research from Venture Economics and the US National Venture Capital Association.
Davis to head private equity at Merrill Lynch, new chairman for Royal Bank Private Equity and two new hires for Amadeus….
Final closing for Gilde, debut fund of funds for Schroders, launch of Kleinwort Capital, second fund of funds for Danske, final close for Brockway Moran, Riverside closes ahead of target....
Danske Private Equity has closed fund-raising for its renamed Venture Partners fund at 1.5bn kroner, including among its investors the European Investment Fund and the US life insurance and investment company Phoenix.
Stocks of biotechnology companies are soaring. But while these companies have promising technologies, they are years away from profits. The boomlet shows, however, how hard it is to value biotech stocks. Analysts often use proxy drivers such as the number of patents or the dollar value of partnerships to value such companies, but these drivers fail to show if the companies will be able to turn their research into marketable products. Research by Karl Ulrich, a Wharton professor of operations and information management, and other colleagues offers insights into a new approach to valuing biotech companies.
Europe to escape the US downturn, Austria allows private equity allocation for pension funds, Pantheon sees slump in portfolio value…
Institutional investor profile, Claus Stenbaek, executive director and partner, Danske Private Equity
Danske Private Equity is part of the Danske Bank Group and runs two direct funds, Danske Venture Partners and Danske Life Sciences. It also runs two fund of funds vehicles, the E500m Danske Private Equity Partners I and Danske Private Equity Partners II, which is currently raising E600m, with a first closing expected before the end of this year. Claus Stenbaek has been with Danske since 2000 and was previously founder of London-based Richmond Capital.
Biotech has traditionally been considered a risky option for investors. But this is no longer the case, argues Dr Hellmut Kirchner of Venture Capital Management. He explains why, in many respects, biotech is now a safer bet for investors than other, more fashionable industries.
Swiss food giant Nestle has announced plans to launch a CHF 200 million corporate venturing fund to invest in strategically attractive small businesses. It will be managed by an independent team and will focus on the food and life sciences sectors.
The German venture capital market has grown rapidly in the last four years but how does it compare to the more mature UK market? This executive summary taken from the CMBOR quarterly review gives an outline of some of Germany's main characteristics.